Loading…
Reported covered position: Legislative Assistant, Office of Sen. Johnny Isakson; Legislative Correspondent, Office of Sen. Saxby Chambliss; Legislative Correspondent, Office of Sen. Zell Miller
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: BAXTER HEALTHCARE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues impacting medical device and technology manufacturers related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF BATTERY RECYCLERS, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Source: Senate LDA
| CHILDREN'S HOSPITAL ASSOCIATION |
| 23 |
| 2013–2019 |
| C.R. BARD INC. | 19 | 2016–2020 |
| CARDINAL HEALTH, INC. | 18 | 2018–2022 |
| INTEGRA LIFESCIENCES CORP. | 18 | 2016–2020 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 17 | 2017–2020 |
| TEXAS CHILDREN'S HOSPITAL | 17 | 2014–2017 |
| CELGENE CORPORATION | 16 | 2016–2019 |
| GILEAD SCIENCES, INC. | 16 | 2016–2019 |
| ONCOSEC MEDICAL INC. | 16 | 2018–2022 |
| BIOIDENTICAL HORMONE REPLACEMENT THERAPY COALITION | 15 | 2019–2022 |
| GAMIDA | 15 | 2020–2024 |
| FERRING PHARMACEUTICALS, INC. | 14 | 2023–2026 |
| HILL-ROM HOLDINGS | 14 | 2019–2022 |
| PATIENTRIGHTSADVOCATE.ORG INC. | 11 | 2024–2026 |
| STRONGBRIDGE BIOPHARMA PLC | 11 | 2018–2020 |
| UROGEN PHARMA LTD. | 11 | 2020–2022 |
| BECTON, DICKINSON AND COMPANY | 10 | 2020–2022 |
| FAEGRE BAKER DANIELS CONSULTING O.B.O. MEDICAL TRANSPORTATION ACCESS COALITION | 10 | 2019–2021 |
| MODIVCARE SOLUTIONS, LLC | 10 | 2024–2026 |
| ADVAXIS, INC. | 8 | 2016–2017 |
| EDGE THERAPEUTICS INC. | 8 | 2016–2018 |
| JS LINK, INC. (FORMERLY DNA LINK CO., LTD.) | 8 | 2025–2026 |
| OPHTHOTECH CORP. | 8 | 2016–2017 |
| STRYKER CORPORATION | 8 | 2025–2026 |
| ARALEZ PHARMACEUTICALS US INC. | 7 | 2016–2017 |
| BLACKBIRD LABORATORIES | 7 | 2025–2026 |
| SOUTHERN RESEARCH | 7 | 2023–2025 |
| INSMED INCORPORATED | 6 | 2018–2019 |
| UNIVERSITY OF ALABAMA HEALTH SYSTEM | 6 | 2025–2026 |
| AMERICAN CHEMISTRY COUNCIL | 5 | 2017 |
| BAXTER HEALTHCARE CORPORATION | 5 | 2022 |
| CORETSU INC. | 5 | 2025–2026 |
| GENENTECH INC | 5 | 2016–2017 |
| PROSPECT MEDICAL HOLDINGS, INC. | 5 | 2017 |
| TYME TECHNOLOGIES, INC. | 5 | 2020 |
| ALIBABA GROUP HOLDING LIMITED | 4 | 2016 |
| ASSOCIATION OF BATTERY RECYCLERS, INC. | 4 | 2026 |
| Portola Pharmaceuticals, Inc. | 4 | 2017 |
| THE MEDICINES COMPANY | 4 | 2016 |
| DEPOMED INC | 3 | 2017 |
| YAMO PHARMACEUTICALS, LLC | 3 | 2018 |
| AEROFLOW HEALTHCARE | 1 | 2017 |
| AVELLA SPECIALTY PHARMACY | 1 | 2015 |
| HEARING INDUSTRIES ASSOCIATION | 1 | 2025 |
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: BAXTER HEALTHCARE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues impacting medical device and technology manufacturers related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Contact Lens Prescription Verification Modernization Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Further Consolidated Appropriations Act, 2020
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2207, the Protect Medical Innovation Act. S. 692, the Protect Medical Innovation Act.
Further Consolidated Appropriations Act, 2020
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Further Consolidated Appropriations Act, 2020
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Further Consolidated Appropriations Act, 2020
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S.692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2207, the Protect Medical Innovation Act. S. 692, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.69, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S.692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.69, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Contact Lens Prescription Verification Modernization Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Clean Water Through Green Infrastructure Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Clean Water Through Green Infrastructure Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Prescription Drug Pricing Reduction Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Policies that promote domestic battery recycling.
Filing targets: Export-Import Bank of the United States (EXIM Bank), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI)
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SIXAXIS LLC via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JS LINK, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Artificial intelligence and technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF BATTERY RECYCLERS, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies that promote domestic battery recycling.
Filing targets: Export-Import Bank of the United States (EXIM Bank), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI)
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SIXAXIS LLC via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODIVCARE SOLUTIONS, LLC via BAKER & HOSTETLER LLP
2026 · second_quarter · 2T
Policy issues related to non-emergency medical transportation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JS LINK, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Artificial intelligence and technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF BATTERY RECYCLERS, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies that promote domestic battery recycling.
Filing targets: Export-Import Bank of the United States (EXIM Bank), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI)
UNIVERSITY OF ALABAMA HEALTH SYSTEM via BAKER & HOSTETLER LLP
2026 · first_quarter · 1T
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SIXAXIS LLC via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODIVCARE SOLUTIONS, LLC via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to non-emergency medical transportation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JS LINK, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Artificial intelligence and technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF BATTERY RECYCLERS, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · RR
Advancing policies to promote battery recycling.
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
UNIVERSITY OF ALABAMA HEALTH SYSTEM via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SIXAXIS LLC via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODIVCARE SOLUTIONS, LLC via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to non-emergency medical transportation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JS LINK, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Artificial intelligence and technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORETSU INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · RR
Artificial intelligence and technology policy issues.
UNIVERSITY OF ALABAMA HEALTH SYSTEM via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SIXAXIS LLC via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODIVCARE SOLUTIONS, LLC via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues related to non-emergency medical transportation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JS LINK, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · RR
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
UNIVERSITY OF ALABAMA HEALTH SYSTEM via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2025 · second_quarter · RR
Policies related to biotech research and laboratory testing models.
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SIXAXIS LLC via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODIVCARE SOLUTIONS, LLC via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues related to non-emergency medical transportation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JS LINK, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF ALABAMA HEALTH SYSTEM via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF ALABAMA HEALTH SYSTEM via BAKER & HOSTETLER LLP
2025 · first_quarter · RR
Policy issues regarding healthcare research, including federal funding.
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SOUTHERN RESEARCH via BAKER & HOSTETLER LLP
2025 · first_quarter · 1T
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIXAXIS LLC via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODIVCARE SOLUTIONS, LLC via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues related to non-emergency medical transportation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JS LINK, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policies to promote domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · first_quarter · RA
Federal regulatory and reimbursement issues relating to medical technologies and devices.
JS LINK, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · RR
Policies to promote domestic manufacturing.
SOUTHERN RESEARCH via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIXAXIS LLC via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODIVCARE SOLUTIONS, LLC via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Policy issues related to non-emergency medical transportation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODIVCARE SOLUTIONS, LLC via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Policy issues related to non-emergency medical transportation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PATIENTRIGHTSADVOCATE.ORG INC. via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Policy issues relating to healthcare price transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOUTHERN RESEARCH via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIXAXIS LLC via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
General manufacturing and workplace safety policy issues.
General manufacturing and workplace safety policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE